Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15833
UPID:
STXB2_HUMAN
Alternative names:
Protein unc-18 homolog 2; Protein unc-18 homolog B
Alternative UPACC:
Q15833; B4E175; E7EQD5; Q9BU65
Background:
Syntaxin-binding protein 2, also known as Protein unc-18 homolog 2 or B, plays a crucial role in intracellular vesicle trafficking and membrane fusion. It is essential for the exocytosis of cytotoxic granules in natural killer (NK) cells, interacting with SNARE proteins to regulate membrane fusion.
Therapeutic significance:
The protein is implicated in Hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, a disorder marked by immune dysregulation and hypercytokinemia. Understanding the role of Syntaxin-binding protein 2 could open doors to potential therapeutic strategies for this and related immune disorders.